Corporate Banner
Satellite Banner
Technology Networks Header
Monday, May 20, 2013
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
Bruker’s Products at ArabLab 2012 Plus Launch of Global Energy Testing Website
Monday, March 26, 2012
Bruker is attending ArabLab 2012 (March 26-29, Dubai, United Arab Emirates) with its industry leading PIONA+™ Analyzer.

Published article now available online “Minimizing False Positives and False Negatives in Pesticide Residue Screening of Grains” with Bruker’s SCION TQ GC-MS
Thursday, February 16, 2012
This article examines how gas chromatography-mass spectrometry-based analysis of pesticide residues in grains often result in enhanced responses (false positive or false negative results), and discusses how the degree of enhancement is dependent on the type of grain under study.

Integrated DNA Technologies Introduces gBlocksTM Gene Fragments
Monday, February 13, 2012
The Company has announced that it is taking orders for a new product that represents a significant advancement for synthetic biology tools.

Global Food Crisis to Spur Sturdy Growth of Genetically Engineered Crop
Tuesday, February 07, 2012
The research report titled "Genetic Engineering: A Global Outlook" announced by Global Industry Analysts, Inc., provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings.

BioNitrogen Unveils Revolutionary Technology
Thursday, January 26, 2012
Utilizing proprietary technology the company is able to convert biomass to high-quality, urea fertilizer for the global marketplace.

Simplified and Cost-Effective New Approach to Carbohydrate Determination
Tuesday, January 24, 2012
Thermo Fisher Scientific announces a new study that evaluates disposable gold on polytetrafluoroethylene (Au on PTFE) working electrodes with multiple application conditions.

Simcyp Develops Virtual Laboratory Mouse for Use in Cancer and Toxicology Research
Friday, January 20, 2012
The Simcyp Mouse provides a virtual environment for evaluating drug disposition which will replace the need for some live animal testing in normal as well as transgenic mice, thus reducing and refining preclinical investigation.

Integromics Announces the Release of SeqSolve 2.1
Monday, January 09, 2012
Integromics(R) has announced the release of SeqSolve 2.1(TM), its analytical software package which provides scalable server mode and makes the analysis of Next Generation Sequencing (NGS) data simpler.

Agilent Technologies Names National Center for Genome Resources as a Certified Provider of Target Enrichment Services
Wednesday, January 04, 2012
National Center for Genome Resources (NCGR) has achieved Certified Service Provider status for the Agilent SureSelect Target Enrichment System for next-generation sequencing. NCGR now provides Agilent exome and custom target-enrichment services along with sequencing and analysis for a wide range of genomics studies.

<< 1 2 3 4 5 6 7 >>
Showing Results 21 - 30 of 73
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Get The App
Go to LabTube.tv
Go to ePosters.net